Independent PatientView Survey
Corporate Reputation of Pharma 2025/26
■ An extensive evidence base of patient-group views
■ 47 companies involved
■ Now in its 15th year
■ Database of 40,000 patient groups worldwide
■ Survey conducted in 23 languages
■ Analyses based on geographic regions and therapy areas
Respondent patient groups 2025/26:familiarity and partnerships with pharma
Specialities of patient-group respondents 2025/26
Country headquarters of respondent patient groups 2025/26
| Pharmaceutical companies included in PatientView’s Corporate Reputation of Pharma 2025/2026:
New companies for 2025/2026 included in bold: * AbbVie * Acadia Pharmaceuticals * Alnylam Pharmaceuticals * Amgen * Amicus Therapeutics * Angelini Pharma * Astellas Pharma * AstraZeneca (including Alexion) * Bayer * Biogen * BioMarin * Boehringer Ingelheim * Bristol Myers Squibb * Chiesi Farmaceutici * CSL Behring * Daiichi Sankyo * Eisai * Eli Lilly * Exelixis * Gilead Sciences * GSK * Incyte * Ipsen * Johnson & Johnson Innovative Medicine (J&JIM) * Jazz Pharmaceuticals * LEO Pharma * Lundbeck * Merck KGaA/EMD Serono * MSD/Merck & Co * Novartis * Novo Nordisk * Otsuka * Pfizer * PTC Therapeutics * Recordati * Regeneron Pharmaceuticals * Roche/Genentech/Chugai * Sanofi * Sarepta Therapeutics * Servier * Sobi * Takeda * UCB * Ultrageny * Vertex * Viatris* ViiV Healthcare |
Click here for more on PatientView’s Corporate Reputation of Pharma report
Key Facts
For more information or to inquire about the Corporate Reputation of Pharma report, please contact PatientView using the form below.